No Detail Found!

Irisin Level in Salah Adin's Insulin Resistance Syndrome Patients in View of Global Controversy

Author(s)
SEDEEM ZEKI SALIH Department of Clinical Chemistry/College of Medicine/Tikrit University
SAMI A ZBAAR Department of Biochemistry College of medicine /Tikrit University
MOHAMED GHALIB ZAKARI Internal Medicine, College of Medicine, Tikrit University
Abstract
Metabolic syndrome (high blood pressure, hyperglycemia, dyslipidemia, and obesity) is now an international health problem that impacts about 20 per cent to 25 per cent of the total population and can be worsened in the developing world, particularly in the Middle East, which is roughly two out of every five Iraqis. The metabolic syndrome has a direct link to many life-threatening diseases, such as cardiovascular disease, early onset of some cancers, such as colorectal cancer, Chronic liver illnesses, polycystic ovarian syndrome, and others. Methodology: A case-control study on a total of ninety volunteers (46 males and 44 females), comprising sixty metabolic syndrome patients (25 males and 35 females), defined in terms of international diabetic federation criteria, and thirty controls, is to be conducted at Salah Alden general hospital. Adults men and women aged (24-to 65) years who attended Salah Alden's main hospital outpatient clinics in Tikrit\Iraq, from October 2021 to March 2022 were included in the research. The levels (Irisin, and Insulin) in all research groups and controls are evaluated using an Enzyme-Linked Immune-sorbent Assay. Results: Irisin level was significantly higher among controls with a mean of (6.84ng/ml), compared to metabolic syndrome patient mean (5.71 ng/ml), and significantly negatively correlated to triglycerides level, and non-significantly negatively correlated with (systolic blood pressure, fasting serum glucose, and waist circumference) and non-significantly positively correlated to high-density lipoprotein level. Irisin levels were significantly different among treatment-based groups with the highest mean level among the treatment-free group (6.8450ng/ml±1.96052), followed by the antihypertensives taking group (5.3340ng/ml±2.99273), and the lowest mean level was recorded among diabetics (4.8916ng/ml±2.81952). Conclusion: With the exception of HDL, a high level of Asprosin and a low level of Irisin are strongly linked to metabolic syndrome and its components. Irisin levels differ amongst metabolic syndrome patients with various therapy groups.
Publication Details
Page(s) 628-631
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 16, Issue: 06, Year: 2022

Request the full text from PASTIC

Keywords
Metabolic syndrome, insulin resistance., Irisin
References
Ansarimoghaddam A. . .Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. , : .
.2018 .. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, : .
. .. , 12(2) : 195-201.
Pengpid K.,Peltzer K. . .Prevalence and associated factors of metabolic syndrome among a national population-based sample of 18-108-year-olds in Iraq: results of the 2015 STEPS survey. , : .
.2021 .. International Journal of Diabetes in Developing Countries, : .
. .. , 41(3) : 427-434.
Al-Azzawi O.F. .2018 .Metabolic syndrome; comparing the results of three definition criteria in an Iraqi sample. AL-Kindy College Medical Journal, 14(2) : 7-12.
MOTAR B.A.,Journal B.A. .2017 .Relation between Metabolic syndrome and acute coronary syndrome and arrhythmia in AL-Nasiriya city. , 12(2) : 79-93.
Kamal B.J.,Ali W.M.,Helal A.S. . .The Prevalence of Metabolic Syndrome among Type 2 Diabetic Patients according to NCEP ATP III and IDF at Baba GurGur Diabetic Center. , : .
Mahmood A.M.,Ahmed M.H.,Mohammad J.B. . .Prevalence of metabolic syndrome in angiographically confirmed coronary artery 7. , : .
.2018 .. Medical Journal of Babylon, 15(4) : 310.
Ismael S.A.,Ahmed H.F.,Hasan M.T. .2016 .Prevalence of metabolic syndrome in a sample of population in Erbil city. Zanco Journal of Medical Sciences (Zanco J Med Sci), 20(2) : 1280-1287.
James M. .2020 .Association between metabolic syndrome and diabetes mellitus according to International Diabetic Federation and National Cholesterol Education Program Adult Treatment Panel III criteria: a Cross-sectional study. Journal of Diabetes & Metabolic Disorders, 19(1) : 437-443.
Stone S.,Bilek S.,Rosenbaum S. .2005 .Recent national cholesterol education program adult treatment panel III update: adjustments and options. The American journal of cardiology, 96(4) : 53-59.
Alberti G. .2006 .The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, : .
.2019 .Síndrome metabólico en pacientes con cáncer de próstata en tratamiento con bloqueo androgénico. , 83 : .
Einhorn D. .2003 .American College of Endocrinology position statement on the insulin resistance syndrome. Endocrine practice, : 5-21.
Alberti K.G. .2009 .International diabetes federation task force on epidemiology and prevention; hational heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; international association for the study of obesity: harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation, 120 : 1640-1645.
Jasiukaitienė V. .2020 .The impact of metabolic syndrome and lifestyle habits on the risk of the first event of cardiovascular disease: Results from a cohort study in lithuanian urban population. Medicina, 56(1) : 18.
Chen H. .2021 .Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut, 70(6) : 1147-1154.
.2021 .. Trends in Endocrinology & Metabolism, 32(7) : 500-514.
de Medeiros S.F. .2021 .The role of visceral adiposity index as predictor of metabolic syndrome in obese and nonobese women with polycystic ovary syndrome. Metabolic Syndrome and Related Disorders, 19(1) : 18-25.
Kumari S.,Kumar R.,Kant R. .2019 .An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(4) : 2409-2417.
Severinsen ,M.C.K B.K.,Pedersen B.K. .2020 .Muscle-organ crosstalk: The emerging roles of myokines. Endocrine reviews, 41(4) : 594-609.
Kim J.A. .2019 .Proportion and characteristics of the subjects with low muscle mass and abdominal obesity among the newly diagnosed and drug-naïve type 2 diabetes mellitus patients. Diabetes & Metabolism Journal, 43(1) : 105-113.
Scariot P.P. .2021 .Aerobic training associated with an active lifestyle exerts a protective effect against oxidative damage in hypothalamus and liver: The involvement of energy metabolism. Brain Research Bulletin, 175 : 116-129.
Xue R. .2021 .Abdominal obesity and risk of CVD: a dose-response meta-analysis of thirty-one prospective studies. British Journal of Nutrition, : 1-11.
Boström P. .2012 .A PGC1-α-dependent myokine that drives brownfat-like development of white fat and thermogenesis. Nature, : .
. .. , 481(7382) : 463-468.
Vliora M.,Acta (BBA)-General Subjects M. .2022 .Irisin regulates thermogenesis and lipolysis in 3T3- L1 adipocytes. , : 130085.
Huh J.Y. .2018 .The role of exercise-induced myokines in regulating metabolism. Archives of pharmacal research, 41(1) : 14-29.
Antioxidants Redox,Signaling Redox .2022 .. , : .
Wang Z. .2021 .Energy metabolism in brown adipose tissue. The FEBS Journal, 288(12) : 3647-3662.
Hartmann M. .2021 .Combined cardioprotective and adipocyte browning effects promoted by the eutomer of dual sEH/PPARγ modulator. Journal of Medicinal Chemistry, 64(5) : 2815-2828.
Kim H.K. .2021 .Comparison of muscle mass and quality between metabolically healthy and unhealthy phenotypes. Obesity, : .
. .. , 29(8) : 1375-1386.
Mengeste A.M.,Rustan A.C.,Lund J. .2021 .Skeletal muscle energy metabolism in obesity. Obesity, 29(10) : 1582-1595.
Alberti ,K.G.M.M. P.,Zimmet J.,Shaw J. .2006 .Metabolic syndrome-a new world‐wide definition. A consensus statement from the international diabetes federation. Diabetic medicine, 23(5) : .
.2022 .Determinants of Metabolic Syndrome (Hypertension and Diabetes Mellitus Type 2). in 3rd International Scientific Meeting on Public Health and Sports (ISMOPHS, : .
Rizk F.H.,Elshweikh S.A.,Abd A.Y. .2016 .Irisin levels in relation to metabolic and liver functions in Egyptian patients with metabolic syndrome. Canadian journal of physiology and pharmacology, 94(4) : 359-362.
Osama B. .2021 .Serum irisin with metabolic syndrome, type II diabetes, and insulin resistance. Journal of Current Medical Research and Practice, 6(3) : 318.
Medicine .2021 .. , 100(5) : .
Yan B. .2014 .Association of serum irisin with metabolic syndrome in obese Chinese adults. PloS one, 9(4) : e94235.
Huerta-Delgado A.S. .2020 .Serum irisin levels, endothelial dysfunction, and inflammation in pediatric patients with type 2 diabetes mellitus and metabolic syndrome. Journal of diabetes research, : .
Song R. .2021 .Lower levels of irisin in patients with type 2 diabetes mellitus: A meta-analysis. Diabetes Research and Clinical Practice, 175 : 108788.
Miazgowski T. .2021 .Associations of circulating irisin with 24-h blood pressure, total and visceral fat, and metabolic parameters in young adult hypertensives. Archives of Endocrinology and Metabolism, 65 : 137-143.
0

Citations

0

Downloads

33

Views